Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Toshio Imai

Showing results (161-170 of 196) with videos related to

Pageof 20
Sort By:
Journal of Breath Research|February 28, 2012
Standardization of clinical protocols in oral malodor researchKen Yaegaki, Donald M Brunette, Albert Tangerman, et al.
European Journal of Immunology|February 21, 2003
Membrane-bound form of fractalkine induces IFN-gamma production by NK cellsOsamu Yoneda, Toshio Imai, Miyuki Nishimura, et al.
International Journal of Molecular Sciences|April 25, 2019
Anti-Apoptotic Effects of Recombinant Human Hepatocyte Growth Factor on Hepatocytes Were Associated with Intrahepatic Hemorrhage Suppression Indicated by the Preservation of Prothrombin TimeSotaro Motoi, Hiroko Toyoda, Takashi Obara, et al.
Carcinogenesis|June 25, 2019
Organoid-based ex vivo reconstitution of Kras-driven pancreatic ductal carcinogenesisTetsuya Matsuura, Yoshiaki Maru, Masashi Izumiya, et al.
Journal of Immunology (Baltimore, Md. : 1950)|November 20, 2009
Role of CX3CL1/fractalkine in osteoclast differentiation and bone resorptionKeiichi Koizumi, Yurika Saitoh, Takayuki Minami, et al.
Modern Rheumatology|January 21, 2023
Long-term evaluation of E6011, an anti-fractalkine monoclonal antibody, in patients with rheumatoid arthritis inadequately responding to biological disease-modifying antirheumatic drugsYoshiya Tanaka, Tsutomu Takeuchi, Hisashi Yamanaka, et al.
Modern Rheumatology|January 11, 2021
A phase 2 study of E6011, an anti-Fractalkine monoclonal antibody, in patients with rheumatoid arthritis inadequately responding to biological disease-modifying antirheumatic drugsYoshiya Tanaka, Tsutomu Takeuchi, Hisashi Yamanaka, et al.
Journal of Neurochemistry|April 16, 2008
Intra-neural administration of fractalkine attenuates neuropathic pain-related behaviourFiona E Holmes, Nighat Arnott, Penny Vanderplank, et al.
Cancer Letters|November 14, 2021
Integrin α5 mediates cancer cell-fibroblast adhesion and peritoneal dissemination of diffuse-type gastric carcinomaShingo Miyamoto, Yoshiko Nagano, Makoto Miyazaki, et al.
Modern Rheumatology|January 21, 2023
Long-term safety and efficacy of E6011, an anti-fractalkine monoclonal antibody, in patients with rheumatoid arthritis inadequately responding to methotrexateYoshiya Tanaka, Tsutomu Takeuchi, Hisashi Yamanaka, et al.
Pageof 20

Showing results (161-170 of 196) with videos related to

Sort By:
Pageof 20
Journal of Breath Research|February 28, 2012
Standardization of clinical protocols in oral malodor researchKen Yaegaki, Donald M Brunette, Albert Tangerman, et al.
European Journal of Immunology|February 21, 2003
Membrane-bound form of fractalkine induces IFN-gamma production by NK cellsOsamu Yoneda, Toshio Imai, Miyuki Nishimura, et al.
International Journal of Molecular Sciences|April 25, 2019
Anti-Apoptotic Effects of Recombinant Human Hepatocyte Growth Factor on Hepatocytes Were Associated with Intrahepatic Hemorrhage Suppression Indicated by the Preservation of Prothrombin TimeSotaro Motoi, Hiroko Toyoda, Takashi Obara, et al.
Carcinogenesis|June 25, 2019
Organoid-based ex vivo reconstitution of Kras-driven pancreatic ductal carcinogenesisTetsuya Matsuura, Yoshiaki Maru, Masashi Izumiya, et al.
Journal of Immunology (Baltimore, Md. : 1950)|November 20, 2009
Role of CX3CL1/fractalkine in osteoclast differentiation and bone resorptionKeiichi Koizumi, Yurika Saitoh, Takayuki Minami, et al.
Modern Rheumatology|January 21, 2023
Long-term evaluation of E6011, an anti-fractalkine monoclonal antibody, in patients with rheumatoid arthritis inadequately responding to biological disease-modifying antirheumatic drugsYoshiya Tanaka, Tsutomu Takeuchi, Hisashi Yamanaka, et al.
Modern Rheumatology|January 11, 2021
A phase 2 study of E6011, an anti-Fractalkine monoclonal antibody, in patients with rheumatoid arthritis inadequately responding to biological disease-modifying antirheumatic drugsYoshiya Tanaka, Tsutomu Takeuchi, Hisashi Yamanaka, et al.
Journal of Neurochemistry|April 16, 2008
Intra-neural administration of fractalkine attenuates neuropathic pain-related behaviourFiona E Holmes, Nighat Arnott, Penny Vanderplank, et al.
Cancer Letters|November 14, 2021
Integrin α5 mediates cancer cell-fibroblast adhesion and peritoneal dissemination of diffuse-type gastric carcinomaShingo Miyamoto, Yoshiko Nagano, Makoto Miyazaki, et al.
Modern Rheumatology|January 21, 2023
Long-term safety and efficacy of E6011, an anti-fractalkine monoclonal antibody, in patients with rheumatoid arthritis inadequately responding to methotrexateYoshiya Tanaka, Tsutomu Takeuchi, Hisashi Yamanaka, et al.
Pageof 20